Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology

MRD Tailored Therapy in AML: What We Have Learned So Far

(2021) Lok Lam Ngai et al.   Frontiers in Oncology

DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells

(2021) Helen Loo Yau et al.   MOLECULAR CELL

Acute myeloid leukemia: current progress and future directions

(2021) Hagop Kantarjian et al.   Blood Cancer Journal

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

(2021) Julian Swatler et al.   Cancers

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

(2021) Julia Stomper et al.   LEUKEMIA

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

(2021) Ling Xu et al.   Frontiers in Oncology

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML

(2021) Franziska Brauneck et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer

(2020) Johanna Waidhauser et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Alterations of T-cell-mediated immunity in acute myeloid leukemia

(2020) Zhuoyan Li et al.   ONCOGENE

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

(2020) David Y. Oh et al.   CELL

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

(2020) Camille-Charlotte Balança et al.   JCI Insight

Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia

(2019) Chetasi Talati et al.   HAEMATOLOGICA

Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?

(2019) Danielle Roberts et al.   Journal of Oncology Practice

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

(2019) Joseph L. Benci et al.   CELL

Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use

(2019) Valeria Santini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming

(2019) Aimee Merino et al.   JOURNAL OF CLINICAL INVESTIGATION

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

(2018) Jeffrey E. Lancet et al.   JOURNAL OF CLINICAL ONCOLOGY

Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience

(2018) Pankit Vachhani et al.   LEUKEMIA RESEARCH

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

(2018) Naval Daver et al.   Cancer Discovery

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

(2017) Liuluan Zhu et al.   Journal of Hematology & Oncology

Immunological effects of hypomethylating agents

(2017) Katherine E. Lindblad et al.   Expert Review of Hematology

Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression

(2017) Tatiana Pazina et al.   Frontiers in Immunology

NK Cell Exhaustion

(2017) Jiacheng Bi et al.   Frontiers in Immunology

NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors

(2017) Alexander W. MacFarlane et al.   OncoImmunology

Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation

(2016) Zhang Zhang et al.   HEMATOLOGICAL ONCOLOGY

Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology

(2016) Vivien Béziat et al.   IMMUNOLOGY

Phenotypic and functional characteristics of CD39highhuman regulatory B cells (Breg)

(2016) F. Figueiró et al.   OncoImmunology

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function

(2015) Heinrich Schlums et al.   IMMUNITY

CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT

(2015) F Cichocki et al.   LEUKEMIA

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation

(2015) Andreas D. Ørskov et al.   Oncotarget

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

(2015) Prakash K. Gupta et al.   PLoS Pathogens

Optimal dose and schedule of consolidation in AML: Is there a standard?

(2014) Charles A. Schiffer   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma

(2014) Jessica Rueff et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in nonobese diabetic mice by increasing Th1 and Th17 cells

(2014) Ming-Hong Lin et al.   CLINICAL IMMUNOLOGY

Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection

(2014) Peiyuan Lu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blimp-1 Attenuates Th1 Differentiation by Repression of ifng, tbx21, and bcl6 Gene Expression

(2014) L. Cimmino et al.   JOURNAL OF IMMUNOLOGY

Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma

(2014) T Zhang et al.   Blood Cancer Journal

Natural killer cell biology: An update and future directions

(2013) Kerry S. Campbell et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cytokine-Dependent Induction of CD4+ T cells with Cytotoxic Potential during Influenza Virus Infection

(2013) L. Hua et al.   JOURNAL OF VIROLOGY

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

The role of hypomethylating agents in the treatment of elderly patients with AML

(2013) Haifa Kathrin Al-Ali et al.   Journal of Geriatric Oncology

DNA demethylation in PD-1 gene promoter induced by 5-azacytidine activates PD-1 expression on Molt-4 cells

(2011) Min Zhang et al.   CELLULAR IMMUNOLOGY

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells

(2010) C. G. Kanakry et al.   BLOOD

Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education

(2010) N. K. Bjorkstrom et al.   BLOOD

Transcriptional Repressor Blimp-1 Promotes CD8+ T Cell Terminal Differentiation and Represses the Acquisition of Central Memory T Cell Properties

(2009) Rachel L. Rutishauser et al.   IMMUNITY

Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses

(2009) Axel Kallies et al.   IMMUNITY

A Role for the Transcriptional Repressor Blimp-1 in CD8+ T Cell Exhaustion during Chronic Viral Infection

(2009) Haina Shin et al.   IMMUNITY